ENXTPA:SANPharmaceuticals
Sanofi (ENXTPA:SAN) Faces MS Setback While Reinforcing Alzheimer’s And Autoimmune Pipeline
Sanofi halted development of tolebrutinib in primary progressive multiple sclerosis after the drug missed its Phase 3 primary endpoint.
The company signed a licensing deal worth up to $1.04 billion with ADEL for an investigational Alzheimer’s antibody.
Sanofi expanded its collaboration with Dren Bio to advance next generation B cell targeted therapies for autoimmune diseases.
Regulatory progress includes approvals for new rare disease medicines in China and EMA orphan designation for an...